Answer
Venous blood clots, including clots in the legs or lungs, are an important risk when amivantamab is combined with lazertinib. Prevention and monitoring are managed by the specialist team.
Sources for this answer
- Rybrevant (amivantamab) 1600mg solution for injection — Current selected SmPCemc · Summary of Product Characteristics
- Rybrevant (amivantamab) 350mg concentrate for solution for infusion — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.